Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
María Elena Cabrera, Neda Marinov, Macarena Roa, Jorge J. Castillo & Estella Matutes. (2022) Epidemiology of chronic lymphocytic leukemia in Chilean and Amerindian population in Chile. Leukemia & Lymphoma 63:5, pages 1137-1143.
Read now
Read now
Ankit Shah & Jacqueline C Barrientos. (2021) Oral PI3K-δ,γ Inhibitor for the Management of People with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Narrative Review on Duvelisib. OncoTargets and Therapy 14, pages 2109-2119.
Read now
Read now
Articles from other publishers (15)
Muhammad Hossein Ashoub, Amirreza Naseri, Parisa Mohammadi & Masoud Mohammadi. (2023) Ofatumumab regimens in chronic lymphocytic leukemia: a meta-analysis. Annals of Hematology 102:6, pages 1301-1306.
Crossref
Crossref
Emelie Curovic Rotbain, Cristine Allmer, Klaus Rostgaard, Michael Asger Andersen, Noomi Vainer, Caspar da Cunha‐Bang, Sameer A. Parikh, Kari G. Rabe, Henrik Hjalgrim, Henrik Frederiksen, Susan L. Slager & Carsten Utoft Niemann. (2023) Impact of type 2 diabetes on mortality, cause of death, and treatment in chronic lymphocytic leukemia. American Journal of Hematology.
Crossref
Crossref
Adrian M. Shields, Sian E. Faustini, Siobhan Young, Sarah Terjesen, Nicholas I. McCarthy, Rachel L. Anderson, Mark T. Drayson & Alex G. Richter. (2023) Clinical and laboratory characteristics of patients with symptomatic secondary immunodeficiency following the treatment of haematological malignancies. eJHaem 4:2, pages 339-349.
Crossref
Crossref
Simone Oerlemans, Fabio Efficace, Jacobien M. Kieffer, Charalampia Kyriakou, Aliki Xochelli, Kerstin Levedahl, Duska Petranovic, Fabio Cardoso Borges, Anne Bredart, Omar Shamieh, Laimonas Gziskevicius, Jens Lehmann, Christian W. Scholz, Giovanni Caocci, Stefano Molica, Kostas Stamatopoulos, Alkistis‐Kyra Panteliadou, Maria Papaioannou, Waleed Alrjoob, Panagiotis Baliakas, Richard Rosenquist, Sandra Malak, Ana Miranda, Kim Cocks & Lonneke van de Poll‐Franse. (2022)
International validation of the
EORTC QLQ‐CLL17
questionnaire for assessment of health‐related quality of life for patients with chronic lymphocytic leukaemia
. British Journal of Haematology 197:4, pages 431-441.
Crossref
Crossref
Monia Marchetti, Paolo Rivela, Claudia Bertassello & Manuela Canicattì. (2022) Comparative Clinical Value of Pharmacologic Therapies for B-Cell Chronic Lymphocytic Leukemia: An Umbrella Analysis. Journal of Clinical Medicine 11:7, pages 1868.
Crossref
Crossref
Lukáš Smolej. 2022.
Adam S. Kittai, Cecelia Miller, Daniel Goldstein, Ying HuangLynne V. Abruzzo, Kyle Beckwith, Seema A. BhatDavid A. Bond, Michael R. GreverNyla A. Heerema, Kerry A. Rogers, Amy S. RuppertJohn C. ByrdJennifer A. Woyach. (2021) The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib. Blood 138:23, pages 2372-2382.
Crossref
Crossref
Fábio Cardoso Borges, Adriana Ramos, António Lourenço, Maria Gomes da Silva & Ana Miranda. (2021) Detailing the epidemiological and clinical characteristics of chronic lymphocytic leukaemia in Portugal—Results from a population-based cancer registry cohort study. PLOS ONE 16:10, pages e0258423.
Crossref
Crossref
Fanny Gallais, Loïc Ysebaert, Fabien Despas, Sandra De Barros, Lucie Obéric, Ben Allal, Etienne Chatelut & Mélanie White‐Koning. (2021) Population PK‐PD Modeling of Circulating Lymphocyte Dynamics in Chronic Lymphocytic Leukemia Patients Under Ibrutinib Treatment. Clinical Pharmacology & Therapeutics 110:1, pages 220-228.
Crossref
Crossref
Lukáš Smolej, Pavel Vodárek, Dominika Écsiová & Martin Šimkovič. (2021) Chemoimmunotherapy in the First-Line Treatment of Chronic Lymphocytic Leukaemia: Dead Yet, or Alive and Kicking?. Cancers 13:13, pages 3134.
Crossref
Crossref
О. B. Kalashnikova, M. O. Ivanova, N. P. Volkov, E. V. Kondakova, E. A. Izmailova, I. M. Barhatov, T. L. Gindina, E. V. Babenko, A. D. Kulagin, N. B. Mikhailova & I. S. Moiseev. (2021) Prognostic factors and effectiveness of the first-line therapy for chronic lymphocytic leukemia: results of 10-year follow-up. The Scientific Notes of the Pavlov University 27:3, pages 80-96.
Crossref
Crossref
ShlanS Muhammad, AhmedKhudair Yassin, RawandP Shamoon, NawsherwanS Mohammed, MarwaNadhim Nadhim, KawaM Hassan, BryarSabah Rashid, ShokhanM Mohammad, Ranan karadagh, GhanimS Numan, LaraLateef Abdulrahman, SanaD Jalal, ZhalaO Ahmed, HishamA Getta, TavanI Mahmood, BasilK Abdulla, DanaA Abdullah, Rozh-hatA Yousif & ZekiA Mohamed. (2021) The significance of Rai and Binet clinical staging on the survival of chronic lymphocytic leukemia patients in the Kurdistan region of Iraq. Iraqi Journal of Hematology 10:2, pages 146.
Crossref
Crossref
Olga Borisovna Kalashnikova, I.S. Moiseev, T.L. Gindina, E.A. Izmailova, M.O. Ivanova, E.V. Kondakova, N.B. Mikhailova & A.D. Kulagin. (2021) Prediction of Treatment Efficacy in Relapsed Chronic Lymphocytic Leukemia. Clinical oncohematology 14:4, pages 466-476.
Crossref
Crossref
Kaladada Ibitrokoemi Korubo, Uchechukwu Prince Okite & Sampson Ibekwe Ezeugwu. (2021) Chronic Lymphocytic Leukemia: Prognostic Factors at Presentation in a Resource-Limited Center. JCO Global Oncology:7, pages 56-62.
Crossref
Crossref
Romeo G. Mihăilă. (2020) Monoclonal Antibodies, Bispecific Antibodies and Antibody-Drug Conjugates in Oncohematology. Recent Patents on Anti-Cancer Drug Discovery 15:4, pages 272-292.
Crossref
Crossref